RBC maintains Outperform on Ariad


RBC's Michael Yee maintains an Outperform rating on Ariad Pharmaceuticals (ARIA).

Yee is looking forward to Iclusig data to be presented at a meeting of the American Society of Hematology this December.

Price target is $28, representing a 25% upside from Friday's close.

See also: Iclusig TRx +5.4% w/w

From other sites
Comments (1)
  • allanong
    , contributor
    Comments (6) | Send Message
     
    Aria has the potential to double its price once its main drug becomes front liner
    8 Sep 2013, 11:06 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs